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ABSTRACT
Controlled drugs are psychoactive drugs with dependence (addiction) and abuse potentials. They evolved from free-trade goods to
scheduled substances that are strictly regulated in the United Nations drug-related Conventions. This paper began with a brief review on the
history of addictive substance abuse in Taiwan. Then the progress of controlled-drug-related law enactment and the functions of National
Narcotics Bureau and its successor, National Bureau of Controlled Drugs, were succinctly depicted. The experiences of substance abuse
prevention and control, which have been accumulated in the past two decades since the methamphetamine deluge, have evolved into a
controlled-drug regulatory system that now conforms to the spirit of the three UN anti-drug Conventions in general and a comprehensive
system for the surveillance and prevention of substance abuse. However, according to the present substance-abuse problems and future
developing trend, it is advised that (1) the operation of scheduling system should be more expertized and the inspection should be further
strengthened; (2) whether the narcotic manufacturing maintains the status quo as a monopoly or seeks privatization should be based on the
benefit of the general public; (3) in addition to the law enforcement from the supply side, a thorough anti-drug strategy should be equipped
with a monitoring and reporting system for early substance-abuse detection and surveillance, a proactive education program that touches
the need of the risk groups and a cost-effective and humanistic treatment program.
Key words: controlled drugs, substance abuse, legislation, drug policy, UN conventions, harm reduction

INTRODUCTION
Controlled drugs refer to a variety of psychoactive drugs
or substances that possess dependence (addiction) and abuse
potentials. Individuals who abuse or misuse such drugs often
enter a miserable relapse cycle(1). Drug (substance) abuse or
misuse not only undermines an individual’s health, but also
results in substantial medical and social problems. As a result,
both national and international authorities impose strict regulations on the flow and use of these drugs.
Current international drug control system originates
from endeavors made a century ago to address the Chinese
opium epidemic, which was regarded as the largest substance
abuse problem the world has ever had(2). This epidemic, as
it is now known to all Chinese, occurring in the nineteenth
century during the reign of Qing Dynasty of China, has
begotten aftermath and legacies, especially in the aspects of
international treaties, conventions and regulations. Although
many countries have exerted efforts in implementing antidrug policy and measures since the epidemic, a truly international cooperation to tackle this global problem did not
* Author for correspondence. Tel: +886-7-3121101 ext. 2651;
Fax: +886-7-3210683; E-mail: jhlitox@kmu.edu.tw

occur until the Shanghai Opium Commission was held in
1909. China, the first and main country plagued by the opium
epidemic, maneuvered to call for such international cooperation(2). The declaration of the Shanghai Opium Commission gradually evolved into the 1961 Single Convention on
Narcotic Drugs(3). Subsequently, the United Nations (UN)
expanded the control of narcotics to psychotropic substances
and precursors by enacting two additional Conventions, i.e.,
the 1971 UN Convention on Psychotropic Substances(4) and
the 1988 UN Convention against Illicit Traffic in Narcotic
Drugs and Psychotropic Substances(5). However, the latter
two UN Conventions did not take effect timely in Taiwan
because Taiwan has been deprived of the UN membership
since 1971. As a result, the methamphetamine epidemic
occurred in the 1990s.
The author, as the last-term director-general of National
Narcotics Bureau and the first-term director-general of
National Bureau of Controlled Drugs under the Department
of Health, Taiwan, R.O.C. from 1994 till 2005, witnessed the
drastic changes in drug abuse situation and was involved in
the law enactment and policy-making of addictive substance
control. Therefore, the author briefly reviews the progress
of legislative and administrative system for the control of
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controlled drugs in Taiwan in the hope of providing references for the future direction.

BRIEF HISTORY OF ADDICTIVE SUBSTANCE
CONTROL IN TAIWAN
I. Japanese Colonial Government and Opium Licensing
Policy (1895-1945)
In the early seventeenth century, opium was a common
commercial product during the Dutch occupation period. As
one of the free-trade goods, opium was readily available.
After the Qing dynasty of China took over Taiwan in the late
seventeenth century, opium smoking has already become a
popular social hobby even though it was officially banned.
In 1895, the Qing dynasty ceded Taiwan to Japan after losing
the Sino-Japan War(6). Opium smoking, with a prevalence
of 6.3% (some 169,000 opium addicts of the total 2,500,000
inhabitants in 1900), was one of the most serious social problems in Taiwan at that time. Then, the colonial government
adopted the “opium licensing” policy by selling opium to
licensed opium addicts with the government monopoly(6).
Such a policy was similar to today’s methadone maintenance
program and alleviated the abuse situation eventually(6).
II. Promulgation of Narcotics Control Act and Establishment
of National Narcotics Bureau on the Mainland
Although the 1909 Shanghai Opium Commission was
the first international cooperation to encounter the global
drug problem, its declaration was non-binding. Therefore,
a genuine binding convention, the International Opium
Convention of The Hague, which was designed to curb shipments of narcotic drugs from non-medical purposes, was held
in 1912 and took effect in 1915(2). Subsequently, under the
mandates of the League of Nations, three main conventions
were further developed in 1925, 1931 and 1936, respectively.
Accordingly, the Republic of China (ROC) on the mainland
enacted and promulgated in 1929 the first law for medical
narcotics control, the Narcotics Control Act(7). The National
Narcotics Bureau (NNB) was thereby established in Nanjing
in 1935 under the Hygiene Research Institute of the Ministry
of Interior to supply narcotics for medical and scientific
purposes(8). However, the breakout of the Second World War
and the invasion of the Japanese military forced the newly
established NNB to meander westward with the Central
Government of ROC to Chongqing, Sichuan(8). The Second
World War ended in 1945 and the NNB resumed its full functions in Nanjing. In 1946, the Shanghai and Beijing sales
branches, as well as the Tianjin and Changsha sales representative offices were established. In 1947, the Taiwan sales
representative office was established. In 1949, all the sales
offices and sales representative offices on the mainland were
seized by the communists due to the civil war. The NNB,
along with a shipment of 26 tons of opium reserve, resumed
its official functions to manufacture, supply, distribute and
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inspect medical narcotics in Taiwan(8).
III. National Narcotics Bureau as a State-run Enterprise from
1959 through 1999 in Taiwan
After World War II, Japan was defeated and the Republic
of China resumed jurisdiction on Taiwan. There were only
some two thousand opium addicts left and Taiwan was essentially drug free in the subsequent two decades (1940s and
1950s)(6). However, sporadic cases of substance abuse were
still observed from time to time. These included glue sniffing
(inhalation of toluene) in the 1960s, pentazocine in the
1970s, and sedatives-hypnotics (secobarbital, amobarbital
and methaqualone) in the early 1980s. It was estimated that
the substance-abuse population would be several thousand
at most(6). As a result, there was no legislation for comprehensive management and control of psychotropic substances,
such as sedatives-hypnotics that were scheduled in the 1971
Convention on Psychotropic Substances(4) at the time.
In 1959, the NNB was categorized as one of the staterun enterprises by the Executive Yuan(8). Therefore, the high
priority of the NNB was to pursue excess surplus in every
fiscal year rather than to prevent medical narcotics from
diversion, resulting in a policy that erroneously deviated from
its original mission.
In 1982, the World Health Organization expressed
concerns over the management of cancer pain and subsequently enacted a guideline for cancer pain relief in 1986(9).
In Taiwan, however, probably due to the profound influence of the Opium War, both physicians and patients were
very conservative towards the narcotic use for cancer pain
treatment. In order to manage the pain problem of cancer
patients, the NNB promulgated the guideline for clinical use
of medical narcotics and the guideline for homecare use of
medical narcotics in terminal cancer patients in 1993, and
collaborated with the Taiwan Pain Society to develop an
educational program that trained the medical professionals on
proper prescription of opioids (mainly morphine) for patients
with cancer pain or in hospice care in 1995(10,11). Meanwhile,
the NNB-affiliated pharmaceutical plant developed the first
new medicine of morphine sulfate controlled-release tablet
(30 mg) in 1996(12) and marketed the product in 1999(10). As
a result, in Taiwan from 1987 to 2010, while the consumptions of codeine and pethidine remained stable, a 33.9-fold
increase in oral morphine consumption was observed(13),
implying the education program did have a beneficial effect
for the cancer patients (Figure 1).

RECENT SITUATION OF SUBSTANCE ABUSE
AND ANTI-DRUG MEASURES
I. Deluge of Methamphetamine Abuse and Revision of the
Obsolete Laws in the 1990s
Along with the lift of martial law and flourishing
economy in Taiwan in the early1990s, methamphetamine
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and 1988) UN drug-related Conventions and followed the
UN drug scheduling system to classify addictive substances
into four schedules. Furthermore, in the new Acts, an addict’s
status was switched from a criminal to a “diseased criminal,”
a term coined to describe the status of an addict who would
obtain full medical and psychosocial treatments in a correction center. The Controlled Drugs Act also authorized the
National Bureau of Controlled Drugs (NBCD), which was
reorganized from the NNB on July 1, 1999, to be responsible
for the control of licit use and flow of controlled drugs(24).

87'88' 89' 90' 91' 92' 93' 94' 95' 96'97' 98'99' 00' 01' 02' 03' 04' 05' 06' 07' 08' 09' 10'

Year
Figure 1. Consumption of oral narcotic analgesics from 1987 to 2010
in Taiwan.

abuse surged with a prevalence of ca. 1% in the total population(14). In addition to the methamphetamine deluge, cases of
heroin abuse also began to increase. To cope with the escalating situation of drug abuse, the Executive Yuan (Cabinet)
organized the Central Anti-Drug Committee (CADC) in
February 1994 to tackle the problem from both supply and
demand sides(15). Under the CADC, three task forces, namely
seizure enforcement, anti-drug education, and addiction treatment, were structured and led by the Ministry of Justice, the
Ministry of Education, and the Department of Health, respectively. However, methamphetamine and its precursors such
as ephedrine and pseudoephedrine, which are not narcotics,
belong to the domains of the 1971 Convention on Psychotropic
Substances and the 1988 United Nations Convention against
Illicit Traffic in Narcotic Drugs and Psychotropic Substances.
Taiwan’s two obsolete anti-drug related laws, i.e., the Act for
Eradication of Narcotics (for illicit narcotics control) and the
Narcotics Control Act (for licit narcotics control), conformed
only to the UN 1961 Single Convention on Narcotic Drugs.
Furthermore, the policy and effectiveness of addiction treatment was hard pressed to be evaluated because incarceration
was the only solution for narcotic addicts as stated in these two
Acts(16). To acquire the experiences of anti-drug programs and
related legislation from other countries, the NNB elaborated
a plan to visit drug control-related institutions and organizations in many countries including the Netherlands, Belgium,
Sweden(17), U.S.A.(18), Malaysia, Singapore(19), Korea(20),
the United Kingdom, France and Germany(21). One of the
main conclusions of the reports from these official visits
pointed to the necessity of immediate law reform to fully
abide by the UN Conventions. Thus, the “Act for Prevention
and Control of Illicit Drug Hazard(22)” was enacted in May
1998 to replace the old “Act for Eradication of Narcotics”.
For licit drug control, the Narcotics Control Act was also
revised and promulgated as the Controlled Drugs Act in June
1999(23).
These two new Acts incorporated all three (1961, 1971

From its establishment in 1999, the NBCD, in collaboration with the Ministry of Justice and the Ministry of Education, endeavored to construct the comprehensive anti-drug
infrastructures that included:
(I) Implementation of drug-flow and use control system
to ensure controlled drugs for medical and scientific purposes:
In accordance with the Controlled Drugs Act(23), addictive
drugs were classified into 4 schedules and a licensing system
was established to mandate all handlers to register when
possessing or using controlled drugs. To prevent diversion or
misuse of controlled drugs, periodical submission of records
of drug flow and use to the NBCD was required by law and
these records were subjected to inspection by the NBCD and
local health bureaus. By the end of 2001, two years after the
establishment of NBCD, 11,531 certificates of controlled
drugs for legal possession (41.53% or 11,531/27,764 of all
professional institutions) and 29,743 licenses for prescription of controlled drugs (70.96% or 29,743/41,915 of all
medicine-related professionals) were issued. As of December
2011, the issued certificates and licenses have steadily
increased to13,760 (41.30% or 13,760/33,317) and 44505
(85.67% or 44,505/51,952), respectively. The functions of the
controlled-drug management system complied with the three
UN anti-drug Conventions. Therefore, when the NBCD was
mandated to merge into the Taiwan Food and Drug Administration (TFDA) in 2010, the scheduling and licensing systems
remained unchanged except that the incumbent agency now
became TFDA.
(II) Implementation of a comprehensive substance
abuse detection and reporting system to monitor the trend
of substance abuse and identify the high-risk groups for
preventive of substance abuse(25). Because misuse or abuse
of schedule I and II drugs are punishable by law, as a result,
the illicit drug use is often underestimated with only a single
surveillance system. Therefore, with the anti-drug measures
implemented in the U.S. and some European countries as
reference(17,18), a comprehensive detection and reporting
system was established. This system was composed of:
1. Data collection subsystem on arrests, seizures and
laboratory testing for urine samples. The data were collected
monthly from the Investigation Bureau, Ministry of Justice;
the National Police Administration, Ministry of Interior;
the Headquarters of Military Police, Ministry of Defense;
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Department of Health, and all local Health Departments.
These data have been useful in monitoring the trend of drug
abuse so that one can evaluate whether the anti-drug measures
are effective in Taiwan. In addition, sharing of drug information from the supply or demand sides is very important in the
international anti-drug efforts. The information sharing has
also played an important role in the collaborative relationship with international anti-drug organizations such as Asian
Multicity Epidemiology Workgroup (AMCEWG) and United
Nations Office on Drugs and Crime (UNODC)(14,25,26).
2. Reporting subsystem for addiction treatment. In
collaboration with the designated medical care institutions
and private institutions for addiction treatment, the toxicology counseling laboratories of the Taipei Veterans General
Hospital and the Kaohsiung Medical University Hospital, the
NBCD set up an on-line reporting channels and a surveillance and reporting system. The system first identified a surge
in the proportion of intravenous drug users (IDUs) among
all addiction treatment admissions (from 34.7% in 2000 to
63.9% in 2004), as well as in the proportion of IDUs sharing
needles (from 4.0% in 2000 to 15% in 2004)(6). The report of
this alarming trend facilitated the implementation of national
harm reduction program by the Department of Health in
Taiwan(27). By the end of 2011, although the proportion
of IDUs among addiction treatment admissions remained
high (68.6%), the proportion of IDUs sharing needles has
decreased to 3.4%.
3. Reporting subsystem of HIV/AIDS from the Center
for Diseases Control, Department of Health. Because of the
association between needle sharing among drug users and
HIV infection, the system served as a real-time sentinel to
monitor the situation of HIV spread due to drug use.
4. National Household survey: In order to understand the
lifetime prevalence of substance abuse in the general population, a cross-sectional study was conducted by the NBCD on
the Greater Taipei area in 2004. The prevalence rate of illicit
drug use was 1.6%. The major illicit drugs were amphetamine,
marijuana, and glue(28). The experiences obtained from this
study were then extended to the lifetime prevalence survey of
substance abuse of the general population in Taiwan by a joint
task force of NBCD, National Health Research Institute and
National Bureau of Health Promotion in 2005(29).
(III) Implementation of national certified laboratory
program for urine drug testing. In 1995, a laboratory certification program, focusing on the detection of amphetamine(s)
and morphine in the urine in response to the heavy burden of
drug testing endured by the local health bureaus, was initiated
by the National Laboratories for Food and Drug Analysis(30).
After the NBCD was established, the program was expanded
and re-implemented in the NBCD to cope with the escalating
drug abuse situation. Some new drugs of abuse, such as
3,4-methylenedioxy-N-methylamphetamine (MDMA) and
ketamine, have been added in this new national certified laboratory program for urine drug testing(31). In 2001, the NBCD
has certified 13 laboratories, which remained the same as of
August 2012. In addition to serving as an objective tool to
detect recent drug use for court referral, urine drug testing
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can also be used to learn the pattern and trend analysis of drug
abuse. In a study conducted by the NBCD on 931 urine specimens with a broad-spectrum drug-screening HPLC system as
the detection tool, the club drug use profile was successfully
evaluated(32).
(IV) Promotion of anti-drug education program in
collaboration with the Ministry of Education. Substance
abuse results from many factors and can be discussed from
a variety of dimensions(33). Because the first-time abuse of
addictive substance occurred in the 12-17 years old, drug
education focusing on the youth was deemed reasonable(33).
According to the mandate from the Act for Prevention and
Control of Illicit Drug Hazard and the assignment of the
CADC, the incumbent agency for drug education program was
the Ministry of Education(15). The NBCD therefore worked
together with the Ministry of Education on drug education by
helping training cadet teachers in the national normal universities and providing professional expertise, skills and knowledge on drug education. For example, a questionnaire survey
was conducted by the NBCD on the high school students who
participated in the anti-drug ambassador campaign to learn
their awareness on the danger of drugs(34). The results were
discussed and incorporated in the drug education materials
for the high school students.
(V) Evaluation of effectiveness of an anti-drug program
or policy from the aspect of total social costs. Although drug
abuse is known to cause a lot of medical and social problems that would eventually lead to tremendous social costs,
it also deserves our attention to see if an anti-drug program
or policy is cost-effective. A study conducted on the social
costs of drug abuse in Taiwan in 1996 found that incarceration and medical treatment cost 2.06 billion NTD and 2.38
billion NTD, respectively. If the costs of human capital of
6.05 billion NTD were added, the total social costs would
sum up to 10.49 billion NTD in 1996(35). At a time when our
resources are limited yet our social problems seem unlimited,
the concept of cost-effectiveness will not only determine the
priority of public issues, but also reasonableness of the costs.

CONCLUSIONs AND FUTURE TREND
As shown in Figure 2, the urine drug testing results indicated that the abuse of methamphetamine, the predominant
substance of abuse in the early 1990s, has been stabilized since
the late 1990s. While the results may imply that the strategies
of supply reduction and demand reduction on methamphetamine abuse have worked, it is also noteworthy that the trend
of heroin and ketamine abuse has been on the rise since early
2000s. In fact, a new trend of heroin use with needle-sharing
and club drug use with unprotected sex may have triggered
the spread of HIV(6). In 2005, harm reduction was adopted by
the Department of Health as a new strategy to curb the drug
problems in addition to two other strategies of supply reduction and demand reduction. Although Taiwan Centers for
Disease Control proclaimed a dramatic 10% decrease in all
new HIV seropositive after implementation of national pilot
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Figure 2. Results of laboratory testing on the urines collected from drug offenders in Taiwan from 1993 through 2011. Methamphetamine and
heroin were the two predominant drugs abused in the 1990s. Heroin is presented as its major metabolite, morphine, in the urine.

harm reduction program (PHRP) in 2005(36), our study(27), by
analyzing the risk and protection factors for HIV incidences
among the regions with and without PHRP, showed that the
methadone maintenance treatment program was associated
with higher HIV incidence, probably due to the concurrent
HIV testing upon admission. Further analysis indicated the
mandatory HIV testing executed in 2004 and the educational
program were essential for the effective HIV control upon
implementing the PHRP(27). Hence, the historical lesson is
that any anti-drug policy should be well planned before its
implementation for the sake of true cost-effectiveness.
The experiences of substance abuse prevention and
control have evolved into a controlled-drug regulatory
system that now conforms to the spirit of three UN anti-drug
Conventions in principle. By the same token, a comprehensive system for monitoring and prevention of substance abuse
has also been established. Albeit we have learned a lesson
from the methamphetamine epidemic, there are potential
threats that await further endeavors:
I. On balance between law enforcement and freedom
from pain and suffering: the scheduling system for new
addictive substances and strength of inspection.
After the Act for Prevention and Control of Illicit Drug
Hazard and the Controlled Drugs Act were enacted, the spirit
of three UN anti-drug Conventions is essentially observed. The
drug scheduling system that classifies addictive substances
into suitable schedules and the licensing system that monitors the drug flow and use are the two main pillars to maintain the integrity of licit controlled-drug use. The licensing
system requires the reports/records submitted or kept by the
licensees inspected from time to time. Without the strength
of inspection to monitor the drug flow and use, the licensing
system alone would not work by itself. Prescription pain
relievers and drug precursors are two important categories
for control. In the U.S., nonmedical use of prescription pain
relievers such as hydrocodone, oxycodone, and morphine in
the past years among the population have been the second
highest in prevalence among illicit drugs, after marijuana

in 2008(37). Control of drug precursors, such as ephedrine
and pseudoephedrine that are used for clandestine methamphetamine manufacture, has been shown to work to reduce
methamphetamine use(38-40).While it is important to prevent
overconsumption or misuse of licit controlled drugs, proper
health care to alleviate pain and suffering, especially cancer
pain, is equally important(41). Therefore, the balance between
law enforcement and pain control should be delicately justified. In addition, to cope with challenges of globalization and
new communication technologies, such as illicit drug shopping through internet, strategies and methods of law enforcement should be reshuffled(41).
With respect to the drug scheduling system, the crisis
may come from new addictive substances that have not
been controlled by the UN scheduling system. Two wellknown examples are ketamine and Salvia divinorum, which
have not yet been scheduled in the UN Conventions but
have been widely abused in the East Asia and in the United
States, respectively(42,43). In Hong Kong, ketamine has even
replaced heroin as the drug of choice among the young drug
abusers since 2000(42). Recently, based on a nine-category
matrix of harm, ketamine has been evaluated as a drug that
is even more harmful than some scheduled drugs, including
cannabis, LSD and Ecstasy (MDMA)(44). For an addictive
substance that has not been listed in the UN Conventions but
has caused serious abuse problems in a country or region,
scheduling of such a substance for control is imperative. In
Taiwan, although ketamine has been classified as a schedule
III drug, the ketamine seizures have been huge in recent
years: from 598.7 kg in 2007, 799.5 kg in 2008, 1186.4 kg in
2009, 2594.3 kg in 2010, to 1371.9 kg in 2011(42).However,
re-scheduling of ketamine has been stalled for years due to
lack of consensus among the members of Committee for
Drug Scheduling. Thus, development of a rational scale for
an objective decision-making of drug scheduling is in need.
II. On supply of medical narcotics and contingency
inventory: privatization or state-run monopoly of narcotic
manufacturing.
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There have been debates on whether the pharmaceutical plant of controlled drugs (PPCD) that is now affiliated
with the TFDA should be privatized. For decades, medical
narcotics were supplied and distributed through a sole source
of government monopoly, the NNB or NBCD. While the
narcotics were conveniently controlled, medical needs were
also successfully met. Since the NNB was re-organized as the
NBCD, the budgets for medical narcotic supply and production had no longer been criticized for profit-making because
the PPCD was not a state-run enterprise. Instead, as an integrated part of the administrative system under the NBCD, it
was in fact easier for drug-flow control. However, the PPCD
is now under the jurisdiction of TFDA whose mission is to
supervise all pharmaceutical products. On January 26, 2011,
the Controlled Drugs Act was revised so that the PPCD is
permitted to operate as a state-run company(45). A draft statute
on the structure and function of the company have been
discussed and passed by the Executive Yuan(46). However,
before the draft is read into law by the Legislative Yuan, there
are several factors that may be worthwhile to ponder:
(I) According to this newly revised Controlled Drugs
Act (45), the status of the company in essence becomes a staterun monopoly again. However, this company is still affiliated
with the TFDA. Therefore, the issue of conflict-of-interest
remains.
(II) During the days of NNB, the licensing system, with
an aim to qualify the holders of controlled drugs and to monitor
the drug flow and use, was not yet established. Therefore, the
operation of a state-run monopoly was reasonable. However,
as such a licensing system has been established, maintenance
of a state-run enterprise may not be so critical. Manufacture,
distribution and sale of medical narcotics by private companies are common in most advanced countries. However,
the current Controlled Drugs Act(45) states manufacture of
schedule I and II drugs is the responsibility of TFDA’s PPCD,
and the reshuffle of PPCD as a state-run company or franchise/entrustment is pending at the Legislativer Yuan. Should
the manufacture of schedule I and II drugs be commissioned,
the function of a state-run company for easy monitoring of
drug flow would no longer exist and thus be replaceable.
(III) Would the reserve of opioids for contingency situations, which has been a national policy for decades, be still
kept by the government? For a company whose goal is profitmaking, it would be a capital loss if large quantity of opioid
reserve is stocked.
(IV) In the long run, would a small company with a
limited capacity for research and development operate costeffectively? Unless the business policy of the company is
shifted to export products, the expansion of the company
would be difficult.
If the government monopoly is to sustain, the strength
and weakness of keeping a state-run company should be evaluated by justifying the total social costs. Whether the narcotic
manufacturing maintains the status quo as a monopoly or
seeks a future privatization should be based on the benefit of
the general public.
III. On enacting a comprehensive strategy for national
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drug policy: In addition to law enforcement from the supply
side, a thorough anti-drug strategy should be equipped
with a monitoring and reporting system for early detection
and surveillance of substance abuse, a proactive education
program that touches the need of the risk groups and a costeffective and humanistic treatment program for addicts.
To detect any new drug that can potentially undermine
our health, a sentinel reporting system should be fully implemented. Such a system can be maneuvered through urine
drug testing or any epidemiological means. In the U.S., for
example, the report of Community Epidemiology Work Group
(CEWG) that integrates drug abuse information of metropolises from both supply and demand sides is very useful in
giving early warning of every emerging major drug trend in
recent decades(47). An early detected drug of abuse can be
very helpful for preventive purposes. An education program
can then be designed to prevent the potential abuse problem.
As study on Drug Abuse Resistance Education (DARE), the
most widely disseminated school-based prevention program
in the United States failed to indicate its effectiveness against
drug use(48), such a result reveals the difficulty in evaluating
the effectiveness of drug education(49).
The effectiveness of drug abuse treatment is often questioned because the relapse rate is relatively high(50). For best
cost-effective results, different treatment models are usually
required for each drug with different pharmacological characteristics and dependent potentials(51,52). Nevertheless, with
the cost of decreasing cocaine consumption by 1% as the indicator of comparison, it was found that treatment programs are
more cost-effective than enforcement programs that included
source-country control, interdiction and domestic enforcement(53). Furthermore, with evidence-based approaches, drug
abuse treatments can significantly reduce drug use and crime,
thus improving health and social function for drug users(54).
Thus, it is highly recommended that our national drug
policy should be elaborated with the concepts of total social
costs and cost-effectiveness so that the budgets for various
anti-drug programs can be reasonably allocated.
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